Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2003 1
2005 1
2011 2
2013 2
2014 1
2017 2
2018 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Uterine sarcomas--recent progress and future challenges.
Seddon BM, Davda R. Seddon BM, et al. Eur J Radiol. 2011 Apr;78(1):30-40. doi: 10.1016/j.ejrad.2010.12.057. Epub 2011 Jan 17. Eur J Radiol. 2011. PMID: 21247711 Review.
Current staging systems have been unsatisfactory, although a new FIGO staging system specifically for uterine sarcomas has now been introduced, and may allow better grouping of patients according to expected prognosis. While the mainstay of treatment of early disease is a …
Current staging systems have been unsatisfactory, although a new FIGO staging system specifically for uterine sarcomas has now been introduc …
Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcoma.
Akin S, Dizdar O, Karakas Y, Turker A, Kars A. Akin S, et al. Curr Probl Cancer. 2018 May-Jun;42(3):344-349. doi: 10.1016/j.currproblcancer.2018.01.011. Epub 2018 Jan 31. Curr Probl Cancer. 2018. PMID: 29576383
Leiomyosarcomas (LMS) are rare tumors with poor prognosis owing to the high rate of recurrent and metastatic disease. ...
Leiomyosarcomas (LMS) are rare tumors with poor prognosis owing to the high rate of recurrent and metastatic disease. ...
Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma.
Vincenzi B, Stacchiotti S, Collini P, Pantano F, Rabitti C, Perrone G, Iuliani M, Baldi A, Badalamenti G, Sanfilippo R, Santini D, Muda AO, Gronchi A, Casali P, Dei Tos AP, Tonini G. Vincenzi B, et al. Br J Cancer. 2017 Jul 25;117(3):340-346. doi: 10.1038/bjc.2017.187. Epub 2017 Jun 22. Br J Cancer. 2017. PMID: 28641307 Free PMC article.
BACKGROUND: The expression of human equilibrative nucleoside transporter 1 (hENT1), the major gemcitabine transporter into cells, has been thoroughly investigated as a predictive marker of response to gemcitabine in pancreatic cancer and biliary tract cancers. ...
BACKGROUND: The expression of human equilibrative nucleoside transporter 1 (hENT1), the major gemcitabine transporter into cells, has been t …
Prolonged disease stability with trabectedin in a heavily pretreated elderly patient with metastatic leiomyosarcoma of the thigh and renal failure: a case report and review of the literature.
Galizia D, Palesandro E, Nuzzo AM, Pignochino Y, Aliberti S, Aglietta M, Grignani G. Galizia D, et al. Oncol Res. 2013;20(10):483-90. doi: 10.3727/096504013x13685487925130. Oncol Res. 2013. PMID: 24308159 Free article. Review.
In the presence of unresectable metastases either doxorubicin- or gemcitabine-based chemotherapy is the standard of treatment. Nevertheless, prognosis remains poor regardless of the selected chemotherapy regimen, and new effective therapeutic agents for patients with advan …
In the presence of unresectable metastases either doxorubicin- or gemcitabine-based chemotherapy is the standard of treatment. Nevertheless, …
Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study.
Ben-Ami E, Barysauskas CM, Solomon S, Tahlil K, Malley R, Hohos M, Polson K, Loucks M, Severgnini M, Patel T, Cunningham A, Rodig SJ, Hodi FS, Morgan JA, Merriam P, Wagner AJ, Shapiro GI, George S. Ben-Ami E, et al. Cancer. 2017 Sep 1;123(17):3285-3290. doi: 10.1002/cncr.30738. Epub 2017 Apr 25. Cancer. 2017. PMID: 28440953 Free PMC article. Clinical Trial.
Temsirolimus in advanced leiomyosarcomas: patterns of response and correlation with the activation of the mammalian target of rapamycin pathway.
Italiano A, Kind M, Stoeckle E, Jones N, Coindre JM, Bui B. Italiano A, et al. Anticancer Drugs. 2011 Jun;22(5):463-7. doi: 10.1097/CAD.0b013e3283442074. Anticancer Drugs. 2011. PMID: 21301319
The immunohistochemical status of PTEN and phosphorylated S6 ribosomal protein was not predictive of the outcome. This exploratory study indicates antitumor activity of temsirolimus in leiomyosarcoma, possibly through a mechanism involving aberration of the PTEN gene. ...
The immunohistochemical status of PTEN and phosphorylated S6 ribosomal protein was not predictive of the outcome. This exploratory st …
Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses.
Roberts NJ, Zhang L, Janku F, Collins A, Bai RY, Staedtke V, Rusk AW, Tung D, Miller M, Roix J, Khanna KV, Murthy R, Benjamin RS, Helgason T, Szvalb AD, Bird JE, Roy-Chowdhuri S, Zhang HH, Qiao Y, Karim B, McDaniel J, Elpiner A, Sahora A, Lachowicz J, Phillips B, Turner A, Klein MK, Post G, Diaz LA Jr, Riggins GJ, Papadopoulos N, Kinzler KW, Vogelstein B, Bettegowda C, Huso DL, Varterasian M, Saha S, Zhou S. Roberts NJ, et al. Sci Transl Med. 2014 Aug 13;6(249):249ra111. doi: 10.1126/scitranslmed.3008982. Sci Transl Med. 2014. PMID: 25122639 Free PMC article.
It is well known, however, that experimental models often do not reliably predict the responses of human patients to therapeutic agents. We therefore used naturally occurring canine tumors as a translational bridge to human trials. ...
It is well known, however, that experimental models often do not reliably predict the responses of human patients to therapeutic agen …
Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
Sutton G, Blessing J, Hanjani P, Kramer P; Gynecologic Oncology Group. Sutton G, et al. Gynecol Oncol. 2005 Mar;96(3):749-52. doi: 10.1016/j.ygyno.2004.11.036. Gynecol Oncol. 2005. PMID: 15721421 Clinical Trial.
Patients received liposomal doxorubicin 50 mg/m2 IV over 1 h. Courses were repeated every 4 weeks until disease progression or adverse side effects supervened. ...Eleven patients (35.5%) had received radiotherapy. A median of 2.0 courses was given (range 1-8). Five …
Patients received liposomal doxorubicin 50 mg/m2 IV over 1 h. Courses were repeated every 4 weeks until disease progression or advers …
Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study.
Gallup DG, Blessing JA, Andersen W, Morgan MA; Gynecologic Oncology Group Study. Gallup DG, et al. Gynecol Oncol. 2003 Apr;89(1):48-51. doi: 10.1016/s0090-8258(02)00136-1. Gynecol Oncol. 2003. PMID: 12694653 Clinical Trial.
Fifteen had prior irradiation and 39 had prior chemotherapy. A median of 2 (range: 1-12) courses was given. Grade 4 neutropenia occurred in 3 (6.3%) patients. ...
Fifteen had prior irradiation and 39 had prior chemotherapy. A median of 2 (range: 1-12) courses was given. Grade 4 neutropenia occur …
Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study.
Rose PG, Blessing JA, Soper JT, Barter JF. Rose PG, et al. Gynecol Oncol. 1998 Aug;70(2):267-71. doi: 10.1006/gyno.1998.5080. Gynecol Oncol. 1998. PMID: 9740703 Free article. Clinical Trial.
RESULTS: Thirty-six patients were entered on this study; 34 were evaluable for toxicity and 29 were evaluable for response. A median of 2 courses were given (range 1-14). Grade 4 neutropenia occurred in 20.6% and grade 4 thrombocytopenia occurred in 5.8%. ...
RESULTS: Thirty-six patients were entered on this study; 34 were evaluable for toxicity and 29 were evaluable for response. A median of 2 …
11 results